PharmaFocus Today – Page 9 – media

Top 10 Global Pharmaceutical Companies in 2025

As the global pharmaceutical industry accelerates toward greater precision, platformization, and innovation, the title of “leading pharmaceutical company” is no longer defined solely by scale. Instead, it reflects multidimensional leadership across market reach, R&D capability, innovation velocity, and therapeutic dominance. This report, compiled by Drugdu.com, analyzes the world’s top 10 pharmaceutical companies based on the latest publicly available data through October 2025, incorporating revenue strength, pipeline depth, innovation capacity, and platform technology adoption. The goal is to help global buyers, exporters, and strategic partners better navigate opportunities in an increasingly competitive environment. I. Ranking Methodology Our 2025 ranking is based on a comprehensive set of indicators, including: Pharmaceutical revenue (2024–2025), including drugs and vaccines Market capitalization & investor confidence (as of October 2025) Core therapeutic focus areas (oncology, immunology, metabolic disease, etc.) Pipeline size & innovation velocity R&D investment as a % of revenue Adoption of advanced platforms (GLP‑1, ADCs, ...
- Source: drugdu
- 635
- November 19, 2025
Lianhuan Pharmaceutical plans to collaborate with Nanjing University to jointly conduct research and development of anti-thrombotic small nucleic acid drugs

Shanghai Securities News (Reporter He Xinyi) – On November 19th, Lianhuan Pharmaceutical announced that the company intends to collaborate with Nanjing University to jointly develop “anti-thrombotic small nucleic acid drugs”, with an investment amount of 15 million yuan. It is known that this cooperation aims to leverage Nanjing University’s strong research capabilities and preliminary research foundation in nucleic acid drugs, combined with the company’s industrialization and clinical development capabilities, to jointly promote the research and commercialization of innovative drugs. https://finance.eastmoney.com/a/202511193568677315.html
- Source: drugdu
- 69
- November 19, 2025
We possess a mature anti-influenza drug—-Compound Paracetamol and Analgin Capsules

According to NBD AI news, an investor asked on the investor interaction platform: As the flu season approaches, does your company have sales of flu-related medications？ Xidian Pharmaceutical (301130.SZ) stated on the platform on November 19th that regarding its existing marketed products, our company has a mature anti-influenza drug– Compound Paracetamol and Analgin Capsule, and an antiviral tablet that will be approved for market in 2025 and is clinically used for treating upper respiratory tract infections and influenza. The company’s ongoing research project “Study on the Intervention Effect of daphnetin on Mice Models of Human Diseases ” has sub-project “Research on the Intervention Effect of daphnetin on Mouse Virus Pneumonia Models”, in which the experimental results showing the safety and effectiveness of rixinzhi in treating viral pneumonia have been obtained. We have also obtained the invention patent “Application of daphnetin in the Preparation of Drugs for Treating Viral Pneumonia”. If ...
- Source: drugdu
- 73
- November 19, 2025
Sinovac’s Trivalent Influenza Vaccine Age Indication Expanded to Cover All Individuals Aged 6 Months and Older

Beijing Sinovac Biotech Co., Ltd. announced that the expanded age indication for its trivalent influenza vaccine An’er Lifu® (0.5ml/dose) has recently been approved by the National Medical Products Administration (NMPA). With this approval, the target population has been broadened to include children from 6 to 35 months old, making the vaccine suitable for all individuals aged 6 months and above. Reported as China’s first preservative-free trivalent influenza vaccine since its 2006 launch, An’er Lifu® serves a critical population. Children aged 6-35 months face high risks of flu complications, making vaccination the most effective and affordable prevention method. Following expanded age approvals for both Sinovac’s quadrivalent and trivalent flu vaccines (0.5ml/dose), the company has now standardized its seasonal vaccine dosages for everyone aged 6 months and above. This milestone will ensure immunization protection for all eligible groups including young children, significantly improving influenza vaccine accessibility across China. In terms of virus ...
- Source: drugdu
- 67
- November 19, 2025
Subsidiary’s Methylprednisolone Sodium Succinate for Injection Obtains Registration Certificate in Panama

Tianjin Pharmaceutical Group announced on the evening of November 18 that its subsidiary, Tianjin Pharmaceutical Group Co., Ltd., has obtained a registration certificate from the Ministry of Health of the Republic of Panama for Methylprednisolone Sodium Succinate for Injection. This milestone signifies that the drug is approved for manufacturing and marketing in the Republic of Panama. Following the product’s registration certificate from the Ministry of Health of the Dominican Republic in April this year, this latest approval marks another significant achievement in the company’s expanding international presence. Methylprednisolone Sodium Succinate for Injection is a corticosteroid medication primarily used for anti-inflammatory therapy, immunosuppressive treatment, managing hematological diseases and cancers, and treating shock.Tianjin Pharmaceutical Group Co., Ltd. submitted its registration application to the Ministry of Health of the Republic of Panama in 2024 and received approval, securing the registration certificate in November 2025. According to the IQVIA database, the global sales of ...
- Source: drugdu
- 62
- November 19, 2025
New antibody strategy shows promise for halting cyst growth in polycystic kidney disease

Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the kidneys. Over time, the painful, growing cysts rob the organs of their function, often leading to dialysis in advanced cases. There is currently no cure. Researchers at UC Santa Barbara, however, have proposed a cyst-targeted therapy that could interrupt the runaway growth of these sacs by leveraging the target specificity of the right monoclonal antibodies – lab-made proteins that are used in immunotherapy. “The cysts just keep growing endlessly,” said UCSB biologist Thomas Weimbs, senior author of the study published in the journal Cell Reports Medicine. “And we want to stop them. So we need to get a drug into these cysts that will make them stop.” This research was funded in part by the National Institutes of Health and the U.S. Department of Defense. Interrupting a runaway process There are a ...
- Source: drugdu
- 63
- November 19, 2025
New AI Might Boost Liver Donations By Highlighting Best Potential Donors

By Dennis Thompson HealthDay ReporterTUESDAY, Nov. 18, 2025 (HealthDay News) — Artificial intelligence (AI) might help more donated livers reach recipients in a usable state by predicting how soon an organ donor will die after being taken off of life support, a new study says. The time between removal of life support and death can’t exceed 30 to 45 minutes, or transplant surgeons will reject a donated liver because it’s less likely to work effectively in a recipient, researchers said. A trained AI model reduced the rate of futile organ procurements by 60% by predicting better than doctors whether a donor is likely to die within that time frame, researchers recently reported in The Lancet Digital Health. “By identifying when an organ is likely to be useful before any preparations for surgery have started, this model could make the transplant process more efficient,” senior researcher Dr. Kazunari Sasaki, a clinical ...
- Source: drugdu
- 50
- November 19, 2025
Biosimilar drug pertuzumab approved for market in the United States can cover all indications of the original product

On November 17th, Shanghai Fuhong Hanlin Biotechnology Co., Ltd. (hereinafter referred to as “Fuhong Hanlin”) announced that its HLX11 (Pertuzumab, US trade name: POHERDY) ®） Approved by the US Food and Drug Administration (FDA), it can be used interchangeably with the original product PERJETA (pertuzumab), becoming the first and only PERJETA biosimilar drug in the United States, covering all indications approved for the original product in the United States. As of now, 7 products of Fosun Pharma have been approved for overseas market, including 4 products approved for market in the United States. The reporter also learned from Fosun Pharma that this is the first pertuzumab biosimilar drug in the United States and the first FDA approved interchangeable biosimilar drug for the treatment of cancer. HLX11 has also submitted listing applications and been accepted in China, Europe, and Canada. Partoluzumab is a monoclonal antibody against HER2 receptor, which is applicable ...
- Source: drugdu
- 77
- November 18, 2025
NIH Funding Cuts Have Affected Over 74,000 People Enrolled in Experiments, a New Report Says

A new report finds over 74,000 people enrolled in experiments have been affected by the National Institutes of Health’s funding cuts Nov. 17, 2025, at 11:00 a.m Source: Associated Press NEW YORK (AP) — Over 74,000 people enrolled in experiments have been affected by the National Institutes of Health’s funding cuts, according to a new report. Between the end of February and mid-August, funding ceased for 383 studies that were testing treatments for conditions including cancer, heart disease and brain disease. The cuts disproportionately impacted efforts to tackle infectious diseases like the flu, pneumonia and COVID-19, researchers found. The funding cuts likely disrupted patients’ lives in different ways. Some may have signed up for trials that never began or got delayed as institutions scrambled for alternate funding. Others could have lost access to medication or been left with an unmonitored device implant. More still could have participated in trials only ...
- Source: drugdu
- 73
- November 18, 2025
FDA Limits Duchenne Gene Therapy After Two Teens Die of Liver Failure

MONDAY, Nov. 17, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) is tightening restrictions on a gene therapy used to treat Duchenne muscular dystrophy after two teenagers died from liver failure linked to the medication. The FDA decision limits the use of Elevidys, made by Sarepta Therapeutics, to boys who are 4 years and older who can still walk, the agency said. It will no longer be allowed for boys who have already lost mobility, something that typically happens around age 12 for patients with Duchenne. Officials said a safety review confirmed that the two teens developed severe liver damage after receiving the infusion. Both later died. The FDA is also adding its strictest boxed warning to highlight the risks of serious liver injury, acute liver failure and death. Sarepta, based in Cambridge, Massachusetts with offices worldwide, told regulators earlier this year that it had already stopped ...
- Source: drugdu
- 56
- November 18, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.